Denosumab A human monoclonal antibody that prevents RANKL-RANK interaction Denosumab (Bone Metabolism Regulator) Denosumab is a new class of osteoporosis treatment called a human monoclonal antibody that prevents RANKL-RANK interaction […]

Romosozumab EVENITY™ (romosozumab injection) Romosozumab, a sclerostin inhibitor, is the first new approach to the treatment of osteoporosis and fracture risk in almost a decade.Romosozumab (EVENITY™) significantly and rapidly (over […]

Bisphosphonate therapy – long term use Recently a study published by Drieling et al in JAGS 2017 described the results of a cohort study of 5120 older women with an […]

Bisphosphonate therapy – long term use Recently a study published by Drieling et al in JAGS 2017 described the results of a cohort study of 5120 older women with an […]

Latest News Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis. May 31, 2024 Health Canada has provided authorization to market Jubbonti® (denosumab […]

There are several risk factors for osteoporosis and osteoporotic fractures including age, sex, fragility fracture after the age of 40, use of glucocorticoid drugs, medications, medical conditions that inhibit absorption […]

Medications that can Cause Bone Loss, Falls and/or Fractures A variety of medications can increase bone loss and/or fall risk: Synthetic Glucocorticoids (e.g. Prednisone) Glucocorticoids are produced naturally by the […]

Treatments Did you know? Osteoporosis leads to fragility fractures. These are broken bones that happen from a minor injury but that have major consequences such as pain, disability and sometimes […]

BONE MINERAL DENSITY TEST A BMD test can tell you whether or not you have osteoporosis Why Should I Get Tested? A risk factor assessment is an important first step […]